Bylavy

Chemical Nameodevixibat
Dosage FormOral pellet (oral; 200 mcg, 600 mcg; Capsule (oral; 400 mcg, 1200 mcg)
Drug ClassInhibitors
SystemDigestive
CompanyAlbireo Pharma Inc.
Approval Year2021

Indication

  • For the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Bylavy (odevixibat) Prescribing Information2021Albireo Pharma Inc., Boston, MA